Par resumes shipment of generic Precedex

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. earlier this week resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic form of Hospira's Precedex injection. The company resumed after a U.S. District Court lifted a temporary restraining order issued in August at Hospira's request. 

 

Par received approval from the Food and Drug Administration last month for its abberviated new drug application for the injection, which is used to sedate non-intubated patients before and/or during surgical and other procedures. U.S. sales of Precedex injection are $156 million, according to IMS Health data.